Skip to main content

Table 5 Association between different CYP19A1 SNP genotypes and the clinico-pathological features of breast cancer (BC)

From: Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population

Clinical features CYP19A1
rs10046 rs7176005 rs700519 rs6493497 rs4646
Body mass index b
n = 221
0.510 0.570 0.811 0.547 0.092
Age at first pregnancy b
n = 195
0.122 0.200 0.825 0.200 0.956
Age at BC diagnosis b
n = 221
0.007 0.681 0.836 0.789 0.921
Allergy a
n = 221
0.936 0.935 0.401 0.967 0.856
Age at menarche b
n = 221
0.989 0.421 0.044 0.405 0.383
Breastfeeding status a
n = 221
0.401 0.095 0.367 0.127 0.721
Age at menopause b
n = 108
0 .290 0.736 0 .002 0 .736 0.797
Family history a
n = 221
0.571 0.121 0.927 0.138 0.123
Co-morbidity a
n = 221
0.104 0.557 0.924 0.566 0.905
Smoking a
n = 216
0.166 0.607 0.059 0.580 0.617
Pathological features
Progesterone receptor status a
n = 198
0.157 0.754 0.867 0.719 0.755
Estrogen receptor status a
n = 191
0.714 0.463 0.159 0.339 0.227
Human epidermal growth factor receptor 2 marker (HER2) a
n = 139
0.945 0.445 0.493 0.485 0.468
Heteromolecular BC markersa
n = 138
0.510 0.788 0.915 0.797 0.754
Tumor differentiation a
n = 197
0.273 0.851 0.918 0.860 0.906
Axillary lymph nodes a
n = 221
0.844 0.793 0.584 0.687 0.297
Tumor stage a
n = 208
0.491 0.118 0.922 0.080 0.236
Histology classification a
n = 209
0.722 0.475 0.407 0.507 0.320
Tumor size b
n = 208
0.726 0.547 0.879 0.472 0.448
Lymph node involvement a
n = 221
0.953 0.681 0.617 0.691 0.022
  1. a Pearson’s chi-squared test was used to determine genotype-phenotype association
  2. b Analysis of variance (ANOVA) test was used to determine genotype-phenotype association
  3. P-Value < 0.0045 considered as significant